A cluster contribution to European life science innovation and competitiveness?

Lund University’s record-breaking recruitment – attracting researchers from around the world

The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work – the company Tataa Biocenter. “Not only did they take our company away

Vaccine skeptic David Geier to lead study on link to autism

The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.

Efter Trumps nedskärningar – nu ska EU locka över amerikanska toppforskare

USA drar in på statliga forskningsanslag – då ser europeiska aktörer sin chans att locka till sig forskarbegåvningar från andra sidan Atlanten.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decided to make a change from within. Life Science Sweden meets Lina Nordquist, Member of Parliament for the Liberals and their spokesperson on healthcare policy, to have a conversation about reality, politics, and the need for writing.

First preterm infants study – a vital step for Neola

After years of developing an advanced lung monitoring system, Neola Medical has received some delightful news: permission to start its first clinical study on preterm born infants.

Link expanderar i Finland – ”Ett betydande tillskott”

Kontraktsforskningsbolaget Link Medical expanderar genom att förvärva finländska branschkollegan CRST Oy.

LINK Medical recruits Swedish CEO

The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.

Anders Göransson ny vd hos Link Medical

Det norska kontraktsforskningsbolaget Link Medical har rekryterat Anders Göransson till tjänsten som ny vd.

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according to a large American study where the connections between GLP-1 receptor agonists and the risk of a variety of health outcomes have been examined.

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner in a column.

Hon ska leda Lipigons kliniska prövningar

Umeåbolaget Lipigon Pharmaceuticals har anställt Isabelle Morin som Head of Clinical Operations.

Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”

In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at Lund University, about research policy, the constant hunt for funding in academia and what constitutes ‘fine research’.

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.

Assignment: Facilitate the retention of foreign researchers

A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.

Failed to read the fine print – lost his life’s work

A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story of a Swedish entrepreneur who was going to raise US venture capital to strengthen his company but lost his life’s work instead.

Study: Popular diabetes drug may be effective against liver disease

After its success in diabetes and weight loss, a new potential therapeutic area has been identified for Ozempic and other GLP1 analogues. A new study links the drug type to a reduced risk of liver damage.

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

High biological age is linked to a higher risk of dementia and stroke

It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher than their actual age are significantly more likely to suffer from dementia and stroke.

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the right patients be found in time, and will the healthcare system’s resources be sufficient? Life Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.